Our in vivo study results evidenced high efficacy against aspergillosis of AMB-MET and LAMB therapies when combined with the AHCC® supplement since, in contrast to the AMB-based monotherapies, AMB-MET/LAMB with AHCC® supplementation displayed statistically significant improvements with respect to the control group in terms of survival and burden reduction. This evidence concerns the gene GRAMD1B and aspergillosis.